Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATRIX-Rare: Precision Cancer Therapy
NCT06119789Phase 2Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Mar 2025
- Primary completion
- Nov 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib, trametinib, dabrafenib + trametinib in malignant neoplasm, sponsored by Oslo University Hospital. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT06119789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06119789.